Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Enochian Biosciences, Inc is a biotechnology business based in the US. Enochian Biosciences shares (ENOB) are listed on the NASDAQ and all prices are listed in US Dollars. Enochian Biosciences employs 10 staff and has a market cap (total outstanding shares value) of USD$136.2 million.
|Latest market close||USD$3.24|
|52-week range||USD$1.95 - USD$6.19|
|50-day moving average||USD$3.0326|
|200-day moving average||USD$3.6106|
|Wall St. target price||N/A|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.48|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-11)||3.24|
|1 month (2020-12-18)||-2.70%|
|3 months (2020-10-16)||-3.86%|
|6 months (2020-07-17)||-21.36%|
|1 year (2020-01-17)||-37.57%|
|2 years (2019-01-18)||-60.49%|
|3 years (2018-01-18)||4.49|
|5 years (2016-01-15)||8.00%|
|Gross profit TTM||USD$0|
|Return on assets TTM||-4.34%|
|Return on equity TTM||-5.78%|
|Market capitalisation||USD$136.2 million|
TTM: trailing 12 months
There are currently 963,114 Enochian Biosciences shares held short by investors – that's known as Enochian Biosciences's "short interest". This figure is 0.1% down from 964,079 last month.
There are a few different ways that this level of interest in shorting Enochian Biosciences shares can be evaluated.
Enochian Biosciences's "short interest ratio" (SIR) is the quantity of Enochian Biosciences shares currently shorted divided by the average quantity of Enochian Biosciences shares traded daily (recently around 72578.296910324). Enochian Biosciences's SIR currently stands at 13.27. In other words for every 100,000 Enochian Biosciences shares traded daily on the market, roughly 13270 shares are currently held short.
However Enochian Biosciences's short interest can also be evaluated against the total number of Enochian Biosciences shares, or, against the total number of tradable Enochian Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Enochian Biosciences's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Enochian Biosciences shares in existence, roughly 20 shares are currently held short) or 0.1334% of the tradable shares (for every 100,000 tradable Enochian Biosciences shares, roughly 133 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Enochian Biosciences.
Find out more about how you can short Enochian Biosciences stock.
We're not expecting Enochian Biosciences to pay a dividend over the next 12 months.
Over the last 12 months, Enochian Biosciences's shares have ranged in value from as little as $1.95 up to $6.19. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Enochian Biosciences's is 0.3945. This would suggest that Enochian Biosciences's shares are less volatile than average (for this exchange).
Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, focuses on development of human therapeutics for infectious diseases and cancers. The company's lead candidate include ENOB-HV-01 for autologous HIV curative treatment. Its pipeline development products consist of ENOB-HV-11, a preventive HIV vaccine; and ENOB-HV-12, a therapeutic HIV vaccine. The company's pipeline development products also include ENOB-HB-01, a coopting Hepatitis B polymerase; ENOB-DC-01, an off-the-shelf DC vaccine pulsed with MCV lysate; ENOB-DC-11 innovative DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intratumoral injection. The company has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Center, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. Enochian Biosciences, Inc. is headquartered in Los Angeles, California.
Steps to owning and managing CVCY, with 24-hour and historical pricing before you buy.
Steps to owning and managing BMTC, with 24-hour and historical pricing before you buy.
Steps to owning and managing TCPC, with 24-hour and historical pricing before you buy.
Steps to owning and managing BCBP, with 24-hour and historical pricing before you buy.
Steps to owning and managing AXS, with 24-hour and historical pricing before you buy.
Steps to owning and managing BWFG, with 24-hour and historical pricing before you buy.
Steps to owning and managing AU, with 24-hour and historical pricing before you buy.
Steps to owning and managing ATEX, with 24-hour and historical pricing before you buy.
Steps to owning and managing AP, with 24-hour and historical pricing before you buy.
Steps to owning and managing ALSN, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.